Transaction Case Studies

Salirasib Japanese Partnership Agreement

Situation Assessment

  • Single product company with a novel, small molecule targeted agent for pancreatic, non-small cell lung and colorectal cancers
  • Salirasib is a direct ras antagonist targeting a pathway highlighted at ASCO 2008 and 2009
  • Locust Walk Partners was engaged after a failed process with an investment bank, where only one partnering meeting was secured

Process Execution

  • Completed commercial assessment on salirasib for three indications including full revenue model supported by market-based assumptions
  • Repositioned the product to avoid confusion with farnesyl transferase inhibitors and secured nine partnering meetings at ASCO
  • Reached decision makers at partners in senior clinical and commercial roles in addition to business development Advised deal structuring and term sheet negotiations

Successful Outcome

  • License agreement with Ono Pharmaceuticals concluded September 1, 2010 after nine months of due diligence and negotiations
  • Undisclosed total deal value but client was pleased with the outcome

View press release »

Back to transactions »


CLIENT: Concordia Pharmaceuticals


Licensing Agreement for Salirasib in Japan